Background {#Sec1}
==========

Antimicrobial resistance has been declared a global threat to public health, as a massive increase in this problem has been observed in different parts of the world \[[@CR1]\]. Although the magnitude of the antimicrobial resistance problem differs by country and geographical region, South-Asia is considered to be a major region for multidrug-resistant (MDR) bacteria \[[@CR2]\]. The reported frequency of MDRs is increasing, putting strain on the public health organizations that are attempting to control this issue in many countries \[[@CR3]\].

The alarming increase in the prevalence of extended-spectrum β-lactamase (ESBL)-producing *Enterobacteriaceae* has serious consequences for treatment outcomes \[[@CR4]\]. *Escherichia coli* and *Klebsiella* spp. are important pathogens isolated from community-acquired and nosocomial-acquired infections, and have been studied extensively \[[@CR5]--[@CR22]\]. The ESBL enzymes produced by these bacteria make them resistant to the first-choice antibiotic therapies that are commonly used. ESBL-positive strains are associated with a delay in the commencement of suitable antibiotic therapy, which consequently lengthens hospital stay and raises hospital costs \[[@CR23]\]. Failure of antibiotic therapy is responsible for higher mortality rates in patients infected with these bacteria \[[@CR24]\].

Epidemiological studies around the world have investigated the prevalence of ESBL-producing *Enterobacteriaceae* and they have seen multiple mechanisms of drug-resistance \[[@CR25]--[@CR33]\]. Several studies on ESBL infection in Asian-pacific region reported 60--80% of such cases were nosocomial-acquired while, remaining were community-acquired infections \[[@CR1], [@CR3], [@CR34]--[@CR39]\]. Over the last decade in Pakistan, an increase in resistance against quinolones has been observed in *Enterobacteriaceae* \[[@CR40]\]. However, not much is known about fluoroquinolone-resistance in ESBLs and its relationship with plasmid-encoded genes.

MDRs are posing a treatment challenge, and are emerging as a major cause of morbidity and mortality worldwide. Unfortunately, proper surveillance and documentation of such pathogens is very limited, especially in developing countries. It has been estimated that more than 70% of antibiotic resistance occurs in the Asia-pacific region of the world, making antimicrobial resistance extremely problematic for Asian countries \[[@CR1]\]. In Pakistan, ESBLs are especially problematic in terms of their contribution to the MDR bacteria problem. From this perspective, we analysed all of the available data regarding the prevalence of ESBL-producing isolates in different regions of Pakistan.

Antimicrobial resistance is on the rise. There are many factors associated with increasing antimicrobial resistance, one of which is ESBL production. The distribution of ESBLs differs in different communities, and every community must design their own protocol regarding the prevention and treatment of such infections \[[@CR41]\]. Developed countries have annual surveillance systems to monitor the impact of antibiotic resistance as well as to determine the causative agents of antibiotic resistant infections. Such surveillance systems are often inadequate in developing countries. This meta-analysis will improve understanding of the distribution and epidemiology of ESBLs with different gene variants in Pakistan. This study also highlights the need to use molecular techniques to determine the different gene variants associated with ESBL-producing bacteria in Pakistan. To our knowledge, this is the first meta-analysis report from Pakistan, which would aid in updating the national treatment guidelines for ESBL infections. The purpose of this study was to determine the pooled prevalence of ESBL-producing *Enterobacteriaceae* with different gene variants in Pakistan.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

This is a descriptive, meta-analysis study and is comprised of different studies reported from within Pakistan.

Literature search and strategy {#Sec4}
------------------------------

A Web-based search using the key words: ESBLs, Pakistan, ESBL genes and *Enterobacteriaceae*, were performed using the electronic databases PubMed, Scopus, PakMedi Net and Web of Science in September 2016. Articles published in the English language were included in the study. A comprehensive search was carried out for publications on the subject of ESBLs from Pakistan. Furthermore, the references cited within the articles were also carefully screened to look for additional relevant publications.

Study selection procedures and criteria {#Sec5}
---------------------------------------

Study selection was carried out by three authors in three steps independently (SH, SA and SR). As a first step, all of the titles and abstracts that were related to the study question were reviewed, and these were included in a group of eligible articles with irrelevant articles being excluded. All articles in the initially selected group were further screened in a second step by reviewing the full details of the articles. As a third step, selected articles were evaluated by other authors specifically for meta-analysis (RAK, NA, H H, SR), which was conducted using software STATA version 14.1 (College Station, Texas, USA) as previously described \[[@CR42]\].

All studies were included based on the following criteria 1) studies that reported the prevalence of ESBLs in any province of Pakistan; 2) studies on bacterial strains isolated from human specimen; 3) all relevant national and international full text original research articles; 4) studies with confirmed ESBLs using phenotypic detection methods; 5) studies that used molecular techniques for ESBL gene variants.

Studies were excluded based on the following criteria 1) studies with incomplete information related to phenotypic ESBL detection methods; 2) duplicate articles, case reports, very small datasets (few strains \< 15), abstracts/titles only, posters and review articles 3) studies on β-lactamases other than ESBL; 4) studies on animals and environmental strains of non-human origin. After reading the full texts, 13 further articles were removed for miscellaneous reasons \[no phenotypic testing for ESBLs was performed (*n* = 3), case reports (*n* = 1), duplicates (*n* = 2), letter or posters (*n* = 2), studies about MBLs (*n* = 2), Studies specific on cancer patients and (mettalo-β-lactamases) MBLs (*n* = 1) and reviews (*n* = 2)\] (Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}).Fig. 1Flowchart of Systematic literature search and article selectionFig. 2Proportion estimates of ESBL-producing *Enterobacteriaceae* in Pakistan. Midpoint of each horizontal line segment shows the proportion estimate of ESBL in each study. Rhombic mark shows the pooled proportion from all studies included

Data extraction {#Sec6}
---------------

The data were extracted by SH, SA and SR from the eligible studies and included. The data extracted from eligible studies consisted of; year of publication, year in which study was conducted, name of authors, location where the study was conducted (different provinces of Pakistan), sample size, strains detected ESBL, phenotypic detection techniques including; the double disc synergy test (DDST), the combination disc test (CDST), the epsilometric test (E-Test) and molecular detection techniques for gene variants (PCR) (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}). Data were extracted and analysed twice to remove any discordance.Table 1Distribution of Articles reviewed regarding ESBL-producing clinical isolates in different regions of PakistanPublication YearStudy YearAuthorsSample sizeESBL positivePhenotypic Detection TestsMolecular detection tests^a^DDST^b^CDST^c^E-Test^d^MICTypes of Genes detectedMost PrevalentPunjab 120022002Shah et al., \[[@CR76]\]37858YESNONONONONENA 220032002--2003Shah et al., \[[@CR77]\]40087YESNONONONONENA 320042002Ali et al., \[[@CR47]\]812366YESNONONONONENA 420062006Mirza et al., \[[@CR66]\]594YESYESYESYESNONENA 520072004--2006Mumtaz et al., \[[@CR78]\]4615YESNONONONONENA 620072005Anwar et al., \[[@CR12]\]324142YESNoNONONONENA 720092006Amin et al., \[[@CR15]\]20040YESNONOYESNONENA 820092007--2008Hafeez et al., \[[@CR6]\]30991094YESNoNONONONENA 920092006--2007Ullah et al., \[[@CR20]\]392106YESNONONONONENA 1020102002--2007Khan et al., \[[@CR79]\]200175YESNONONONONENA 1120122007--2008Riaz et al., \[[@CR22]\]1018300YESYESNONONONENA 122011--Riaz et al., \[[@CR8]\]1018300YESYESYESNONONENA 1320112009--2010Ejaz et al., \[[@CR11]\]13,638698YESNoNONONONENA 1420112010Hussain et al., \[[@CR45]\]12178YESNONONOAmpC, Class A β-lactamasesCTX-M 1520112008--2009Roshan et al., \[[@CR80]\]308308YESYESNONONONENA 162011--Hassan et al., \[[@CR81]\]10064YESNONONONONENA 1720122006--2009Mehmod et al., \[[@CR58]\]4200408NONONONOAmpCsNA 1820132005,2010Habeeb et al., \[[@CR82]\]17382YESYESNONONONENA 1920132011Begum et al., \[[@CR48]\]9191YESYESNOYESNONENA 2020132010--2012Ejaz et al., \[[@CR9]\]710214YESYESNONONONENA 2120132011--2012Amin et al., \[[@CR10]\]22133YESYESNONONONENA 2220132012Qureshi et al., \[[@CR13]\]672103NOYESNONONONENA 2320132009Hanan et al., \[[@CR44]\]10371YESNONONONONENA 2420132009--2010Khalid et al., \[[@CR83]\]824364YESNONONONONENA 2520132009--2010Habeeb et al., \[[@CR16]\]2525YESNONONOTEM,SHV,OXA,CTX-MTEM 2620132011Day et al., \[[@CR69]\]1140300YESNONONOCTX-M, SHVCTXM 2720132008Shafiq et al., \[[@CR18]\]1328511NONONOYESNONENA 282014--Sabir et al., \[[@CR84]\]500271YESNONONONONENA 2920142011--2013Kausar et al., \[[@CR46]\]225121YESNONONONONENA 3020142011--2013Saboor et al., \[[@CR85]\]38512707YESNONONONONENA 3120152012--2014Sohail et al., \[[@CR86]\]1429382YESNONONONONENA 322015--Khan et al., \[[@CR14]\]2400381NONOYESNONONENA 332015--Riaz et al., \[[@CR7]\]1018815YESYESYESNOTEM, SHV, OXAOXA 342015--Ahmed et al., \[[@CR87]\]1362484YESNONONONONENA 3520162015--2016Ali et al., \[[@CR17]\]250148YESNONOYES*Qnr*genes*qnrB* 3620162014Jamil et al., \[[@CR88]\]4617YESNONONONONENA 3720162005Anwar et al., \[[@CR89]\]12146YESYESNONONONENAKhyberPakhtunkhawa 3820092005--2006Ullah et al., \[[@CR20]\]34266YESYESNONONONENA 3920092006--2007Ullah et al., \[[@CR49]\]9254YESNONONONONENA 4020112009Mumtaz et al., \[[@CR90]\]4150371YESNONONONONENA 4120132013Bari et al., \[[@CR21]\]1037495YESNONONONONENA 4220142012Ilyas et al., \[[@CR19]\]19550YESNONONONONENA 4320142013Bari et al., \[[@CR21]\]1037443YESNONONONONENA 442014--Iqbal et al., \[[@CR91]\]4010379YESNONONONONENA 4520162013--2014Rahman et al., \[[@CR50]\]355157YESNONOYESTEM-1, CTX-M 1CTX-M 1 4620162010--2014Ahmed et al., \[[@CR59]\]3450138YESYESNONONONENASindh 4720032002Jabeen et l., \[[@CR92]\]471140YESYESNONONONENA 4820052002Jabeen et l., \[[@CR93]\]28401137YESNONONONONENA 492009--Ahmed et al., \[[@CR94]\]50040YESNONONONONENA 5020102007--2008Khan et al., \[[@CR79]\]6565YESNOYESNONONENA 5120101990--2006Jabeen et al., \[[@CR95]\]1967120NONONOYESNONENA 5220102002--2007Khan et al., \[[@CR96]\]15,9145016NOYESNONONONENA 5320112008Afridi et al., \[[@CR97]\]4492190YESNONONONONENA 542011--Hassan et al., \[[@CR98]\]10054NOYESNOYESNONENA 5520122008Afridi et al., \[[@CR99]\]190190YESNONONONONENANA (Not applied)^a^DDST (Double Disc Synergy Test)^b^CDST (Combination Disc Test)^c^E-Test (Epsilometric Test)^d^MIC(Minimum Inhibitory Concentration)Table 2Proportion estimates of ESBLs in different regions of PakistanStudyES \[95% Conf. Interval\]% WeightPunjab, Lahore Anwar et al., 2007 \[[@CR12]\]0.440.380.491.83 Hafeez et al., 2009 \[[@CR6]\]0.350.340.371.85 Amin et al., 2009 \[[@CR15]\]0.150.110.201.82 Riaz et al., 2011 \[[@CR8]\]0.290.270.321.84 Ejaz et al., 2011 \[[@CR11]\]0.050.050.061.85 Riaz et al., 2012 \[[@CR22]\]0.290.270.321.84 Mehmod et al., 2012 \[[@CR58]\]0.100.090.111.85 Ejaz et al., 2013 \[[@CR9]\]0.300.270.341.84 Qureshi et al., 2013 \[[@CR13]\]0.150.130.181.84 Hanan et al., 2013 \[[@CR44]\]0.690.590.781.79 Sabir et al., 2014 \[[@CR84]\]0.540.500.591.84 Sohail et al., 2015 \[[@CR86]\]0.270.240.291.84 Riaz et al., 2015 \[[@CR7]\]0.800.770.821.84 Anwar et al., 2016 \[[@CR89]\]0.380.290.471.8 Sub-total Random pooled ES0.330.210.4625.66Punjab, Islamabad Shah et al., 2002 \[[@CR76]\]0.150.120.191.83 Shah et al., 2003 \[[@CR77]\]0.220.180.261.83 Ali et al., 2004 \[[@CR47]\]0.450.420.491.84 Mirza et al., 2006 \[[@CR101]\]0.070.020.161.74 Mumtaz et al., 2007 \[[@CR78]\]0.330.200.481.71 Ullah et al., 2009 \[[@CR20]\]0.270.230.321.83 Khan et al., 2010 \[[@CR79]\]0.200.150.261.82 Hussain et al., 2011 \[[@CR45]\]0.640.550.731.80 Roshan et al., 2011 \[[@CR80]\]1.000.991.001.83 Habeeb et al., 2013 \[[@CR82]\]0.470.400.551.81 Hassan et al., 2011 \[[@CR81]\]0.640.540.731.78 Begum et al., 2013 \[[@CR48]\]1.000.961.001.78 Day et al., 2013 \[[@CR69]\]0.260.240.291.84 Shafiq et al., 201 \[[@CR18]\]0.380.360.411.84 Amin et al., 2013 \[[@CR10]\]0.880.820.921.82 Khalid et al., 2013 \[[@CR83]\]0.440.410.481.84 Habeeb et al., 2013 \[[@CR82]\]1.000.861.001.62 Saboor et al., 2014 \[[@CR84]\]0.700.690.721.85 Akram et al., 2014 \[[@CR5]\]0.540.470.601.82 Khan et al., 2015 \[[@CR14]\]0.160.140.171.85 Ahmed et al., 2016 \[[@CR59]\]0.360.330.381.84 Ali et al., 2016 \[[@CR47]\]0.590.530.651.82 Jamil et al., 2016 \[[@CR88]\]0.370.230.521.71 Sub-total Random pooled ES0.500.390.6241.46Khyber Pakhtunkhawa Ullah et al., 2009 \[[@CR49]\]0.190.150.241.83 Mumtaz et al., 2010 \[[@CR90]\]0.090.080.101.85 Ullah et al., 2010 \[[@CR100]\]0.590.480.691.78 Bari et al., 2013 \[[@CR21]\]0.480.450.511.84 Ilyas et al., 2014 \[[@CR19]\]0.260.200.321.82 Iqbal et al., 2014 \[[@CR91]\]0.090.090.101.85 Bari et al., 2014 \[[@CR21]\]0.430.400.461.84 Rahman et al., 2016 \[[@CR50]\]0.440.390.501.83 Ahmed et al., 2016 \[[@CR59]\]0.040.030.051.85 Sub-totaRandom pooled ES0.260.150.3916.48Sindh Jabeen et l., 2003 \[[@CR92]\]0.300.260.341.83 Jabeen et l., 2005 \[[@CR93]\]0.400.380.421.85 Ahmed et al., 2009 \[[@CR94]\]0.080.060.111.84 Khan et al., 2010 \[[@CR96]\]1.000.941.001.75 Jabeen et l., 2010 \[[@CR95]\]0.060.050.071.85 Khan et al., 2010 \[[@CR96]\]0.320.310.321.85 Afridi et al., 2011 \[[@CR97]\]0.040.040.051.85 Hassan et al., 2011 \[[@CR98]\]0.540.440.641.78 Afridi et al., 2012 \[[@CR99]\]1.000.981.001.81 Sub-total Random pooled ES0.430.270.6016.4Overall Random pooled ES0.400.340.47100.00

Statistical analysis and reporting {#Sec7}
----------------------------------

Statistical analysis was performed using the *Metaprop* command in STATA version 14.1 (College Station, Texas, USA) to pool the published data regarding the predominance of ESBLs in different regions of Pakistan. Statistical heterogeneity was calculated using the I^2^ statistic (measure of inconsistency) at the significance level of 5%. Heterogeneity was used to study the variation in studies using the I^2^ statistic*.* The *p*-values (typically considered significant at 0.05) were used for converting meta-analysis results to defined/known tests of statistics. Random-effects model (REM) was used to estimate the pooled prevalence and 95% CI. A funnel plot and Begg tests were performed to evaluate the publication partiality using data graphically and statistically.

Results {#Sec8}
=======

Distribution of articles describing ESBLs in Pakistan {#Sec9}
-----------------------------------------------------

Electronic database searches yielded a total of 68 studies. A total of 55 articles reviewed from four provinces of Pakistan included 14 (25.4%) from Punjab, 23 (41.8%) from the Islamabad/Rawalpindi, 9 (16.4%) from the KPK, while the remaining 9 (16.4%) were from the Sindh. No studies were found from Baluchistan province (Fig. [3](#Fig3){ref-type="fig"} and Table [3](#Tab3){ref-type="table"}). The maximum number of articles on this subject was published in year 2013, followed by 2011, with the number of published articles in Pakistan decreasing afterwards (Fig. [4](#Fig4){ref-type="fig"}). In total, 42 (76.4%) of the articles reviewed included cases from in-patient and out-patient departments (OPD), 10 (15%) included patients attending in-patient departments, and 3 (6.3%) included patients attending OPD. A total of 21, 232 ESBL-bacterial isolates were included in the analysis. A total of 53 (96.4%) of the reviewed studies were conducted on both adults and children, while only 2 (3.6%) studies were based solely on the paediatric population. No studies were found on male and females separately (Table [2](#Tab2){ref-type="table"}).Fig. 3Distribution of articles in three regions of PakistanTable 3Distribution of published articles in different regions of PakistanYearPunjabKPKSindhAnnual Total Publications20021 (2.7%)0 (0%)0 (0%)1 (1.81%)20031(2.7%)0 (0%)1 (11.1%)2 (3.63%)20041(2.7%)0 (0%)0(0%)1 (1.81%)20050(0%)0 (0%)1 (11.1%)1 (1.81%)20061(2.7%)0 (0%)0(0%)1 (1.81%)20072 (5.4%)0 (0%)0(0%)2 (3.63%)20080 (0%)0 (0%)0(0%)0(0%)20093 (8.1%)2 (22.2%)1 (11.1%)6 (10.9%)20101(2.7%)0 (0%)3 (33.3%)4 (7.27%)20115 (13.5%)1 (11.1%)2 (22.2%)8 (14.5%)20122 (5.4%)0 (0%)1 (11.1%)3 (5.45%)201310 (27%)1 (11.1%)0(0%)11 (20%)20143(8.1%)3 (33.3%)0(0%)6 (10.9%)20154(10.8%)0 (0%)0(0%)4 (7.27%)20163(8.1%)2 (22.2%)0(0%)5 (9.09%)Region-Wide379955Fig. 4Annual publication of articles in different regions of Pakistan

Laboratory methods used to estimate the proportion of ESBLs {#Sec10}
-----------------------------------------------------------

For the variable phenotype methods, out of 55 studies, 48 (87.3%) had performed the double disc synergism test (DDST). However, only 13 (23.6%) had performed the combination disc test (CDST), and only 5 (9.09%) had performed the epsilometric test (E-Test). None of the studies had used the broth minimum inhibitory concentration (MIC) method. Out of 55 studies, 28 (50.9%) were published in local journals while the remaining 27 (49.1%) were in international journals (Table [2](#Tab2){ref-type="table"}).

Molecular methods used to estimate the proportion of ESBLs {#Sec11}
----------------------------------------------------------

For molecular detection methods, 6 (11%) out of 55 articles reported PCR-based gene detection methods. Among these, 50% of articles reported CTX-M group as the most prevalent group, and CTXM-1 as the most commonly found gene variant. Additionally, CTX-M and TEM combinations were found in 33% of selected articles. One study reported the association of *qnrB* genes with the appearance of the ESBLs phenotype (Table [1](#Tab1){ref-type="table"}).

Prevalence of ESBLs and their distribution in different geographical areas of Pakistan {#Sec12}
--------------------------------------------------------------------------------------

Based on the available data (Table [1](#Tab1){ref-type="table"}), Pakistan's overall pooled proportion of ESBL-production was 0.40 (95% CI: 0.34--0.47). The overall heterogeneity was significant (I^2^ = 99.75%, *p* \< 0.001), and significant ES = 0 (Z = 18.41, *p* \< 0.001). The pooled proportion of ESBL-production for the Punjab, the Islamabad/Rawalpindi region, the KPK and the Sindh regions was 0.33 (95% CI: 0.21--0.46), 0.50 (95% CI: 0.39--0.62), 0.26 (95% CI: 0.15--0.39) and 0.43 (95% CI: 0.27--0.60) respectively. Significant heterogeneity (I^2^) for four regions with *p* \< 0.001 is 99.77, 99.46, 99.59 and 99.81% respectively. Significant ES = 0 at *p* \< 0.001 for the Punjab, the Islamabad/Rawalpindi, the KPK and the Sindh regions is Z = 8.32, 12.65, 7.43 and 7.87 respectively (Fig. [2](#Fig2){ref-type="fig"} and Table [2](#Tab2){ref-type="table"}).

Discussion {#Sec13}
==========

To address the issue of MDR bacteria, it is necessary to raise awareness about the magnitude of the problem by collecting data about antibiotic-resistance in various countries and regions \[[@CR1], [@CR29], [@CR43]\]. The scarcity of studies available from Pakistan warrants attention for future research. Limited data regarding the overall predominance of ESBLs from Pakistan are available, but with no studies specifically from Baluchistan. This is the first meta-analysis about the extent of the ESBL problem in the Pakistani population. This is the first meta-analysis regarding the extent of the ESBL problem in the Pakistani population. However, this meta-analysis finds a high percentage of ESBL-producing *Enterobacteriaceae* across different geographical regions of Pakistan \[[@CR5], [@CR7], [@CR12], [@CR20], [@CR44]--[@CR50]\].

This meta-analysis is comprised of different studies reported from within Pakistan. The overall pooled proportion for ESBLs in this meta-analysis for Pakistan was 40% (Table [2](#Tab2){ref-type="table"}). In China, a nationwide survey comprised of 30 different hospitals reported a 46% ESBL proportion, which is quite close to the data reported in our study \[[@CR51]\]. A survey conducted in the hospitals of East Africa reported an overall pooled ESBL proportion of 42% (95% CI: 0.34--0.50) \[[@CR52]\]. Previous research showed a considerably higher frequency of ESBL in Asian and African countries compared to developed countries \[[@CR53]\]. For instance, the German population showed the estimated ESBL proportion in the range of 10 to 15% \[[@CR54]\]. Similarly, a report was published from the US in 2012, which was based on the surveillance of ESBLs in nine census regions of the US, and they reported 4 to 12% resistance due to ESBLs \[[@CR55]\]. However, among the Asian continent, an increase in ESBL mediated resistance was observed among the Japanese community, where the pooled ESBL proportion increased from 6.3% to 20% in 9 years \[[@CR56]\].

These results indicate an extensive and statistically significant degree of disparity in ESBL proportion estimates (*p* \< 0.05). The variation in ESBL occurrence reported in this systematic report may depend on several factors, including the socio-economic status of a society and the availability of antibiotics \[[@CR57]\]. Moreover, differences in the sensitivity and specificity of the different methods applied in determining the proportions are also contributing factors. The majority of studies used purely phenotypic approaches, while some studies used molecular methods along with phenotypic testing \[[@CR7], [@CR9], [@CR16], [@CR17], [@CR44], [@CR47], [@CR49], [@CR58], [@CR59]\]. Differences in ESBL proportions have been documented from all over the world established by hospital or community-based surveys \[[@CR60]--[@CR62]\]. In a study conducted in Ha'Emek Medical Center Israel\> 50% ESBL prevalence was reported for community-acquired infections \[[@CR63]\]. Whereas studies in Egypt, Cameroon, Bamako, Spain, China, Saudi Arabia, United Kingdom, United States, Latin America between 2004 to 2008 indicated a prevalence of ESBLs between 10 and 61% in different hospital and community settings \[[@CR63]--[@CR68]\].

Due to limited resources and a lack of infrastructure, only a few articles (11%) have investigated the molecular characterization and presence of ESBL encoding genes \[[@CR4], [@CR7], [@CR16], [@CR24], [@CR29], [@CR44], [@CR45], [@CR50], [@CR51], [@CR58]\]. OXA, SHV, TEM and CTX-M were the most commonly found gene variants in these studies for ESBLs \[[@CR7], [@CR16], [@CR17], [@CR50], [@CR69]\]. The CTX-M group was found to be prevalent in 50% of studies reporting utilization of PCR-based molecular detection methods. The CTXM-15 gene variant of CTX-M group 1 has already been reported in many studies in the Asian continent \[[@CR70]--[@CR73]\]. In particular, CTXM and TEM is a common gene variant combination \[[@CR7], [@CR50]\]. One study reported the association of *qnrB* gene variants with the appearance of an ESBL phenotype, as this gene is involved in fluoroquinolone resistance \[[@CR17]\]. However, few studies have reported the incidence of NDM genes, which are responsible for Carbapenem-resistance \[[@CR52]\]. There are many reasons for variations in ESBL prevalence in the four studied regions of Pakistan. There may be substrate preferences, higher use of any specific class of antibiotics, co-resistances to other classes of antibiotics, poor health and diagnostic facilities \[[@CR74], [@CR75]\]. With this limited available information to hand, it is challenging to plan intensive and effective interventions for combating the problem of resistance.

Conclusion and recommendations {#Sec14}
==============================

This meta-analysis indicated that there is a high ESBL burden in Pakistan. Few papers are available that address the annual frequency of ESBLs and their distribution in different provinces of Pakistan. No paper is available regarding the frequency of ESBLs in Baluchistan. Only 6 papers that reported gene detection were found. Detection of gene variants in β-lactamase-producing bacteria is essential information for the appropriate and effective treatment of patients. This underscores an urgent demand for regular surveillance to address this antimicrobial resistance issue. National and regional guidelines would be based upon such surveillance in order to understand the annual ESBLs burden. Effective measures such as the establishment of active surveillance and infection control programmes, emphasizing hand hygiene together with coherent antibiotic policies in hospitals and clinics should be implemented to stop and manage the spread of ESBLs in hospitals and communities.
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